Pzena Investment Management LLC Has $390.13 Million Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

Pzena Investment Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 1.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,816,852 shares of the company’s stock after purchasing an additional 153,870 shares during the period. Fresenius Medical Care AG & Co. KGaA accounts for about 1.3% of Pzena Investment Management LLC’s investment portfolio, making the stock its 25th largest position. Pzena Investment Management LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $390,128,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $36,000. Atlantic Union Bankshares Corp bought a new stake in Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $43,000. Hantz Financial Services Inc. grew its position in Fresenius Medical Care AG & Co. KGaA by 568.5% in the second quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after acquiring an additional 1,768 shares in the last quarter. Huntington National Bank increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% during the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock worth $67,000 after purchasing an additional 1,618 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 2nd quarter valued at $73,000. Institutional investors own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Erste Group Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Truist Financial set a $28.00 price objective on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Zacks Research lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings downgraded Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 5th. Five research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Price Performance

NYSE FMS opened at $24.01 on Thursday. The stock has a 50-day simple moving average of $23.29 and a 200 day simple moving average of $24.47. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46. The stock has a market capitalization of $13.92 billion, a PE ratio of 17.52, a P/E/G ratio of 0.78 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.